

Janet A Dunn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1107190/publications.pdf>

Version: 2024-02-01

118
papers

12,178
citations

47006

47
h-index

26613

107
g-index

122
all docs

122
docs citations

122
times ranked

16170
citing authors

#	ARTICLE	IF	CITATIONS
1	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	10.7	148
2	Multi-omic machine learning predictor of breast cancer therapy response. <i>Nature</i> , 2022, 601, 623-629.	27.8	187
3	Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial. <i>Oral Oncology</i> , 2021, 113, 105112.	1.5	16
4	Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial. <i>British Journal of Haematology</i> , 2021, 192, 997-1005.	2.5	6
5	Low serum 1,25(OH)2D3 in end-stage renal disease: is reduced 1 α -hydroxylase the only problem?. <i>Endocrine Connections</i> , 2021, 10, 1291-1298.	1.9	3
6	Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. <i>Radiotherapy and Oncology</i> , 2020, 142, 52-61.	0.6	11
7	Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone. <i>Radiology</i> , 2020, 297, 622-629.	7.3	24
8	Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training. <i>PLoS ONE</i> , 2020, 15, e0238593.	2.5	2
9	Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management. <i>Blood Cancer Journal</i> , 2020, 10, 114.	6.2	8
10	Protective strategies to prevent trastuzumab-induced cardiotoxicity – Authors' reply. <i>Lancet</i> , The, 2020, 395, 492-493.	13.7	0
11	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020, 11, 312.	12.8	30
12	Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-12 Trial (SELECT-12m). <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 905-915.	3.8	56
13	Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-190.	2.8	11
14	Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-70.	0.7	0
15	Levofloxacin prophylaxis in patients with myeloma – Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e69.	10.7	0
16	Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1760-1772.	10.7	109
17	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. <i>Lancet</i> , The, 2019, 393, 2599-2612.	13.7	225
18	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	6.4	52

#	ARTICLE	IF	CITATIONS
19	The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. <i>Journal of Clinical Epidemiology</i> , 2019, 106, 108-120.	5.0	49
20	Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. <i>Lancet</i> , The, 2019, 393, 51-60.	13.7	697
21	Low serum 25-hydroxyvitamin D is associated with increased bladder cancer risk: A systematic review and evidence of a potential mechanism. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 188, 134-140.	2.5	9
22	Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-94.	2.8	3
23	An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. <i>Journal of Clinical Epidemiology</i> , 2018, 99, 75-83.	5.0	25
24	Double Reading in Breast Cancer Screening: Cohort Evaluation in the CO-OPS Trial. <i>Radiology</i> , 2018, 287, 749-757.	7.3	26
25	Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. <i>BMC Cancer</i> , 2018, 18, 391.	2.6	6
26	Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). <i>Journal of Clinical Oncology</i> , 2018, 36, 2017-2023.	1.6	967
27	Radical treatment of muscle-invasive bladder cancer—are options equal?. <i>Journal of Radiation Oncology</i> , 2018, 7, 181-186.	0.7	0
28	Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. <i>Leukemia</i> , 2018, 32, 1727-1738.	7.2	50
29	Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 755-769.	10.7	18
30	Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. <i>Modern Pathology</i> , 2017, 30, 1069-1077.	5.5	15
31	A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines. <i>BMC Medical Research Methodology</i> , 2017, 17, 108.	3.1	31
32	Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. <i>Value in Health</i> , 2017, 20, 1311-1318.	0.3	31
33	Management of hot flushes in UK breast cancer patients: clinician and patient perspectives. <i>Journal of Psychosomatic Obstetrics and Gynaecology</i> , 2017, 38, 276-283.	2.1	14
34	PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. <i>Health Technology Assessment</i> , 2017, 21, 1-122.	2.8	52
35	Management of advanced nodal disease in patients treated with primary chemoradiotherapy. <i>Current Opinion in Oncology</i> , 2016, 28, 201-204.	2.4	3
36	Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw050.	6.3	166

#	ARTICLE	IF	CITATIONS
37	Effect of Using the Same vs Different Order for Second Readings of Screening Mammograms on Rates of Breast Cancer Detection. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1956.	7.4	25
38	Management of Advanced Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 491-493.	27.0	9
39	Trastuzumab-associated cardiac events in the Persephone trial. <i>British Journal of Cancer</i> , 2016, 115, 1462-1470.	6.4	23
40	A genomic approach to therapeutic target validation identifies a glucose-lowering <i><i>GLP1R</i></i> variant protective for coronary heart disease. <i>Science Translational Medicine</i> , 2016, 8, 341ra76.	12.4	100
41	Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 21.	5.0	66
42	Geographic variation in human papillomavirus-related oropharyngeal cancer: Data from 4 multinational randomized trials. <i>Head and Neck</i> , 2016, 38, E1863-9.	2.0	41
43	PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 1444-1454.	27.0	503
44	Prevalence and treatment of hypovitaminosis D in the haemodialysis population of Coventry. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 164, 214-217.	2.5	1
45	Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. <i>British Journal of Cancer</i> , 2016, 114, 381-387.	6.4	56
46	Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTEMIS trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1014-1014.	1.6	3
47	The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study. <i>PLoS ONE</i> , 2016, 11, e0158984.	2.5	15
48	The role of PET CT in the management of advanced nodal head neck cancer post chemoradiotherapy. <i>Translational Cancer Research</i> , 2016, 5, S932-S932.	1.0	1
49	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-202.	2.8	53
50	The use of early decision modelling and value of information analysis in an adaptive trial design: results from the OPTIMA preliminary study. <i>Trials</i> , 2015, 16, .	1.6	0
51	Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean?. <i>BMC Medicine</i> , 2015, 13, 234.	5.5	39
52	A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. <i>BMC Medicine</i> , 2015, 13, 306.	5.5	26
53	A “new normal”™: Exploring the disruption of a poor prognostic cancer diagnosis using interviews and participant-produced photographs. <i>Health (United Kingdom)</i> , 2015, 19, 451-472.	1.5	35
54	Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , 2015, 17, 58.	5.0	26

#	ARTICLE	IF	CITATIONS
55	A review of the issues and challenges involved in using participant-produced photographs in nursing research. <i>Journal of Advanced Nursing</i> , 2015, 71, 1726-1737.	3.3	32
56	Under-representation of male patients in breast cancer studies. <i>Trials</i> , 2015, 16, .	1.6	0
57	Use of patient diaries in conjunction with standard reporting methods: duplication of data or a valuable resource?. <i>Trials</i> , 2015, 16, .	1.6	1
58	Practicalities of using an adaptive design for decision making within the optimal trial: optimal personalized treatment of early breast cancer using multi-parameter tests. <i>Trials</i> , 2015, 16, .	1.6	0
59	Predicting Anthracycline Benefit: <i>TOP2A</i> and <i>CEP17</i> Not Only but Also. <i>Journal of Clinical Oncology</i> , 2015, 33, 1680-1687.	1.6	55
60	PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. <i>Annals of Oncology</i> , 2015, 26, 1488-1493.	1.2	234
61	Identification of Novel Genetic Markers of Breast Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	56
62	Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 656-666.	10.7	114
63	FKBPL: a marker of good prognosis in breast cancer. <i>Oncotarget</i> , 2015, 6, 12209-12223.	1.8	13
64	Abstract P6-08-11: UK OPTIMA-prelim study demonstrates economic value in more clinical evaluation of multi-parameter prognostic tests in early breast cancer. , 2015, , .		0
65	A qualitative systematic review exploring lay understanding of cancer by adults without a cancer diagnosis. <i>Journal of Advanced Nursing</i> , 2014, 70, 1688-1701.	3.3	22
66	Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel. <i>Clinical Cancer Research</i> , 2014, 20, 2466-2475.	7.0	91
67	Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2x2 factorial randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 201-212.	10.7	106
68	Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. <i>Lancet Oncology</i> , The, 2014, 15, 620-630.	10.7	96
69	Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 78-86.	10.7	516
70	PERSEPHONE: Duration of trastuzumab with chemotherapy in patients with HER2-positive early breast cancer—Six versus twelve months.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS656-TPS656.	1.6	4
71	Pulmonary rehabilitation programme for patients undergoing curative lung cancer surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 44, e266-e271.	1.4	56
72	Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. <i>International Journal of Cancer</i> , 2013, 133, 1470-1478.	5.1	15

#	ARTICLE	IF	CITATIONS
73	LIHNCS - Lugol™s iodine in head and neck cancer surgery: a multicentre, randomised controlled trial assessing the effectiveness of Lugol™s iodine to assist excision of moderate dysplasia, severe dysplasia and carcinoma in situ at mucosal resection margins of oral and oropharyngeal squamous cell carcinoma: study protocol for a randomised controlled trial. <i>Trials</i> , 2013, 14, 310.	1.6	17
74	OP077. <i>Oral Oncology</i> , 2013, 49, S35.	1.5	0
75	Thoracoscore fails to predict complications following elective lung resection. <i>European Respiratory Journal</i> , 2012, 40, 1496-1501.	6.7	44
76	Options for early breast cancer follow-up in primary and secondary care - a systematic review. <i>BMC Cancer</i> , 2012, 12, 238.	2.6	28
77	UK ethnicity data collection for healthcare statistics: the South Asian perspective. <i>BMC Public Health</i> , 2012, 12, 243.	2.9	18
78	Feasibility of recruitment to an oral dysplasia trial in the United Kingdom. <i>Head & Neck Oncology</i> , 2012, 4, 40.	2.3	6
79	The Value of Source Data Verification in a Cancer Clinical Trial. <i>PLoS ONE</i> , 2012, 7, e51623.	2.5	58
80	Phase III Randomized Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer: Final Results of the VICTOR Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 4575-4580.	1.6	81
81	Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). <i>Lancet Oncology</i> , The, 2010, 11, 266-274.	10.7	122
82	Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5513-5518.	1.6	708
83	National randomised controlled trial is needed. <i>BMJ: British Medical Journal</i> , 2008, 336, 461.3-462.	2.3	4
84	Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 360-369.	27.0	124
85	A prospective study to assess the value of MMP-9 in improving the appropriateness of urgent referrals for colorectal cancer. <i>BMC Cancer</i> , 2006, 6, 251.	2.6	5
86	Evaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care population. <i>BMC Cancer</i> , 2006, 6, 258.	2.6	18
87	Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer. <i>New England Journal of Medicine</i> , 2006, 355, 1851-1862.	27.0	178
88	Nursing student attitudes to psychiatric nursing and psychiatric disorders in New Zealand. <i>International Journal of Mental Health Nursing</i> , 2005, 14, 103-108.	3.8	59
89	Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival. <i>British Journal of Haematology</i> , 2005, 130, 542-548.	2.5	41
90	Influence of Surgical Resection and Post-Operative Complications on Survival following Adjuvant Treatment for Pancreatic Cancer in the ESPAC-1 Randomized Controlled Trial. <i>Digestive Surgery</i> , 2005, 22, 353-363.	1.2	68

#	ARTICLE	IF	CITATIONS
91	Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002â€”Medical Research Council Adult Leukaemia Working Party. <i>Journal of Clinical Oncology</i> , 2005, 23, 9219-9226.	1.6	402
92	Socio-economic deprivation and survival in bladder cancer. <i>BJU International</i> , 2004, 94, 539-543.	2.5	17
93	A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 1200-1210.	27.0	2,442
94	Progress by Collaboration: ESPAC Studies. , 2004, , 57-69.		0
95	Influence of Resection Margins on Survival for Patients With Pancreatic Cancer Treated by Adjuvant Chemoradiation and/or Chemotherapy in the ESPAC-1 Randomized Controlled Trial. <i>Annals of Surgery</i> , 2001, 234, 758-768.	4.2	560
96	Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. <i>British Journal of Haematology</i> , 2001, 113, 1035-1043.	2.5	160
97	A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix. <i>Annals of Oncology</i> , 2000, 11, 1175-1182.	1.2	35
98	Long–Term Risk of Salvage Cystectomy after Radiotherapy for Muscle–Invasive Bladder Cancer. <i>European Urology</i> , 2000, 38, 279-286.	1.9	26
99	A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. <i>British Journal of Haematology</i> , 1998, 100, 317-325.	2.5	292
100	MRC trial of \pm 2b-interferon maintenance therapy in first plateau phase of multiple myeloma. <i>British Journal of Haematology</i> , 1998, 101, 195-202.	2.5	32
101	Observer variability among colposcopists from the West Midlands region. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1997, 104, 1380-1384.	2.3	52
102	Randomised trial of immediate versus deferred treatment strategies for the management of minor cervical cytological abnormalities. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1997, 104, 590-594.	2.3	52
103	Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. <i>British Journal of Cancer</i> , 1996, 73, 972-978.	6.4	88
104	Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer. <i>British Journal of Cancer</i> , 1995, 71, 1106-1110.	6.4	53
105	Etoposide protein binding in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 506-512.	2.3	40
106	Etoposide protein binding in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 506-512.	2.3	0
107	Evaluation of Pepsinogen A and Gastrin-17 as Markers of Gastric Cancer and High-Risk Pathologic Conditions. <i>Scandinavian Journal of Gastroenterology</i> , 1994, 29, 1129-1134.	1.5	31
108	Pathogenesis of gall stones in Crohn's disease: an alternative explanation.. <i>Gut</i> , 1994, 35, 94-97.	12.1	62

#	ARTICLE	IF	CITATIONS
109	Cigarette smoking and histological outcome in wom with mildly dyskaryotic cervical smears. BJOG: an International Journal of Obstetrics and Gynaecology, 1994, 101, 49-52.	2.3	29
110	The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet, The, 1994, 343, 1309-1312.	13.7	281
111	Pregnancy outcome after large loop excision of the cervical transformation zone. American Journal of Obstetrics and Gynecology, 1993, 169, 620-625.	1.3	72
112	Impact of adjuvant chemotherapy in breast cancer on response to tamoxifen at relapse. Cancer Treatment Reviews, 1993, 19, 11-19.	7.7	5
113	Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. BJOG: an International Journal of Obstetrics and Gynaecology, 1992, 99, 590-594.	2.3	91
114	Is Stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. BJOG: an International Journal of Obstetrics and Gynaecology, 1992, 99, 54-58.	2.3	75
115	The selection of cases for randomised trials: a registry survey of concurrent trial and non-trial patients. British Journal of Cancer, 1992, 66, 943-950.	6.4	40
116	Prognostic indices: Who needs them?. Contemporary Clinical Trials, 1992, 13, 381-382.	1.9	0
117	Retrospective analysis of 318 cases of uterine sarcoma. European Journal of Cancer & Clinical Oncology, 1991, 27, 1095-1099.	0.7	83
118	Lesion size and histology of atypical cervical transformation zone. BJOG: an International Journal of Obstetrics and Gynaecology, 1991, 98, 490-492.	2.3	29